Call +44 (0)1904 798634 or +44 (0)7550 079918

Leading provider of life science market reports and research services

OpportunityAnalyzer: Vasculitis - Opportunity Analysis and Forecast to 2024

Be the first to review this product

OpportunityAnalyzer: Vasculitis - Opportunity Analysis and Forecast to 2024

Summary

Vasculitis is a family of rare autoimmune diseases, causing inflammation of the blood vessels, arteries, veins or...
You can choose to pay by purchase order during checkout

Availability: In stock

$10,995.00

* Required Fields

You can choose to pay by purchase order during checkout
GlobalData.

Digital downloads direct to your inbox within 24 hours.

First class customer service from our team of experts.

Pay by credit card or request an invoice

Product Description

Details

OpportunityAnalyzer: Vasculitis - Opportunity Analysis and Forecast to 2024

Summary

Vasculitis is a family of rare autoimmune diseases, causing inflammation of the blood vessels, arteries, veins or capillaries. The different forms of vasculitis are classified by the size and location of the affected blood vessels . This report specifically covers large vessel vasculitis (LLV), Kawasaki disease (KD), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and Beh

Additional Information

Additional Information

Publisher name GlobalData.
Format PDF
Page count 258
Publication date 1 Jan 2016
Table of contents 1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 15
1.2 List of Figures 19
2 Introduction 20
2.1 Catalyst 20
2.2 Related Reports 21
2.3 Upcoming Related Reports 21
3 Disease Overview 22
3.1 Types of Vasculitis 22
3.2 Etiology and Pathophysiology 23
3.2.1 Large Vessel Vasculitis 23
3.2.2 Kawasaki Disease 24
3.2.3 ANCA-Associated Small Vessel Vasculitis 25
3.2.4 Beh_et's Disease 26
3.3 Symptoms 26
3.4 Disease Management 27
3.4.1 Classification Criteria 27
3.4.2 Disease Management Guidelines 28
4 Epidemiology 34
4.1 Disease Background 34
4.2 Risk Factors and Comorbidities 35
4.3 Global Trends 36
4.4 Forecast Methodology 39
4.4.1 Sources Used 41
4.4.2 Sources Not Used 61
4.4.3 Forecast Assumptions and Methods 61
4.5 Epidemiological Forecast for Vasculitis, 2014-2024 85
4.5.1 Diagnosed Incident Cases of AAV 85
4.5.2 Diagnosed Prevalent Cases of AAV 87
4.5.3 Age-Standardized Incidence of AAV 89
4.5.4 Diagnosed Incident Cases of LVV - TA and GCA 92
4.5.5 Diagnosed Prevalent Cases of TA 94
4.5.6 Age-Standardized Incidence of LVV 96
4.5.7 Diagnosed Incident Cases of BD 98
4.5.8 Diagnosed Prevalent Cases of BD 100
4.5.9 Age-Standardized Incidence of BD 102
4.5.10 Diagnosed Incident Cases of KD 103
4.6 Discussion 105
4.6.1 Epidemiological Forecast Insight 105
4.6.2 Limitations of the Analysis 106
4.6.3 Strengths of the Analysis 107
5 Current Treatment Options 109
5.1 Overview 109
5.2 Product Profiles 111
5.2.1 Rituxan (Rituximab) 111
5.2.2 Humira (Adalimumab) 115
5.2.3 Remicade (Infliximab) 120
5.2.4 Mycophenolate Mofetil 125
5.2.5 Cyclophosphamide 129
5.2.6 Azathioprine 133
5.2.7 Methotrexate 137
5.2.8 Glucocorticoids 140
5.2.9 Intravenous Immunoglobulin 143
6 Unmet Needs Assessment and Opportunity Analysis 147
6.1 Overview 147
6.2 Improved Drug Efficacy and Safety in the Induction Therapy Setting 148
6.2.1 Unmet Need 148
6.2.2 Gap Analysis 149
6.2.3 Opportunity 151
6.3 Improved Drug Efficacy and Safety in the Maintenance Therapy Setting 151
6.3.1 Unmet Need 151
6.3.2 Gap Analysis 152
6.3.3 Opportunity 153
6.4 Biomarkers to Predict Responsiveness to Therapy 154
6.4.1 Unmet Need 154
6.4.2 Gap Analysis 154
6.4.3 Opportunity 154
6.5 Biomarkers to Predict Disease Relapse 155
6.5.1 Unmet Need 155
6.5.2 Gap Analysis 155
6.5.3 Opportunity 156
6.6 Early and Non-invasive Diagnosis of Vasculitis 156
6.6.1 Unmet Need 156
6.6.2 Gap Analysis 157
6.6.3 Opportunity 158
6.7 Adjunctive Therapy for the Treatment of KD 158
6.7.1 Unmet Need 158
6.7.2 Gap Analysis 160
6.7.3 Opportunity 161
7 R&D Strategies 163
7.1 Overview 163
7.2 Expansion for Key Autoimmune Drugs 163
7.3 Shift Towards Vasculitis as a Primary Indication 164
7.4 Clinical Trial Design 165
7.4.1 Current Clinical Trial Design 166
7.4.2 Challenges in Vasculitis Clinical Trial Design 169
8 Pipeline Assessment 171
8.1 Overview 171
8.2 Promising Drugs in Clinical Development 171
8.2.1 Orencia (Abatacept) 172
8.2.2 Benlysta (Belimumab) 176
8.2.3 Actemra (Tocilizumab) 180
8.2.4 Otezla (Apremilast) 184
8.2.5 Nucala (Mepolizumab) 188
8.3 Additional Drugs in Development for Vasculitis 192
9 Pipeline Valuation Analysis 195
9.1 Clinical Benchmark of Key Pipeline Drugs 195
9.1.1 AAV 195
9.1.2 LVV 196
9.1.3 KD 196
9.1.4 BD 197
9.2 Commercial Benchmark of Key Pipeline Drugs 198
9.2.1 AAV 198
9.2.2 LVV 199
9.2.3 KD 199
9.2.4 BD 200
9.3 Competitive Assessment 202
9.3.1 AAV 202
9.3.2 LVV 203
9.3.3 KD 204
9.3.4 BD 204
9.4 Top Line Ten Year Forecast 205
9.4.1 US 210
9.4.2 5EU 212
9.4.3 Japan 213
10 Appendix 215
10.1 Bibliography 215
10.2 Abbreviations 234
10.3 Methodology 240
10.4 Forecasting Methodology 240
10.4.1 Percent Drug-treated Patients 240
10.4.2 Drugs Included in Each Therapeutic Class 240
10.4.3 Launch and Patent Expiry Dates 241
10.4.4 General Pricing Assumptions 242
10.4.5 Individual Drug Assumptions 243
10.4.6 Generic Erosion 251
10.4.7 Pricing of Pipeline Agents 251
10.5 Primary Research 252
10.5.1 Physicians and Specialists Included in this Study 252
10.5.2 Online Survey of High Prescribing Physicians 253
10.6 About the Authors 254
10.6.1 Author 254
10.6.2 Reviewer 254
10.6.3 Epidemiologist 255
10.6.4 Global Director of Therapy Analysis and Epidemiology 255
10.6.5 Global Head of Healthcare 256
10.7 About GlobalData 257
10.8 Disclaimer 257

Reviews

Write Your Own Review

Only registered users can write reviews. Please, log in or register

Product Tags

Product Tags

Use spaces to separate tags. Use single quotes (') for phrases.